Physician profile
Anibal Drelichman
NPI 1740222447
$13,361.16
in general payments reported to CMS, 2019-2025
49 companies · $402 in 2025
The $402 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $99.95 · 2021: $29.53 · 2022: $291 · 2023: $1,408 · 2024: $940 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,378 · Education: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,378.08 |
| Education | $372.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $8,492.49 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $370.47 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $337.59 | 2019-2024 | Darzalex, Tecvayli, Carvykti |
| Aveo Pharmaceuticals, INC. | $324.91 | 2022-2025 | Fotivda |
| Gilead Sciences, INC. | $322.46 | 2019-2023 | Trodelvy |
| Astellas Pharma US INC | $305.80 | 2019-2024 | Xtandi, Padcev |
| Eisai INC. | $273.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $255.89 | 2019-2025 | Calquence, Tagrisso, Imfinzi |
| Daiichi Sankyo INC. | $210.44 | 2022-2024 | Enhertu, Injectafer |
| Smith+Nephew, INC. | $206.54 | 2019 | |
| Genentech USA, INC. | $201.14 | 2019-2024 | Polivy, Lunsumio, Columvi |
| Sobi, INC | $175.54 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $137.62 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $133.86 | 2019 | |
| Clovis Oncology, INC. | $124.99 | 2019 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $117.35 | 2019-2023 | Blincyto, Kyprolis, Vectibix |
| Sanofi-Aventis U.S. LLC | $99.95 | 2020 | |
| Lilly USA, LLC | $98.08 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Genzyme Corporation | $81.52 | 2019-2024 | |
| Emd Serono, INC. | $73.06 | 2019-2023 | Tepmetko |
| Celgene Corporation | $67.71 | 2019-2024 | Reblozyl, Pomalyst |
| Pfizer INC. | $66.10 | 2019-2022 | |
| Seagen INC. | $64.66 | 2023 | Tukysa, Padcev |
| Beigene USA, INC. | $63.21 | 2022-2024 | Brukinsa |
| Apellis Pharmaceuticals, INC. | $55.65 | 2024-2025 | Empaveli |
| Taiho Oncology, INC. | $52.52 | 2019-2024 | |
| Exelixis INC. | $48.19 | 2024-2025 | Cabometyx |
| Recordati_rare_diseases_inc. | $45.68 | 2024 | Sylvant |
| Alexion Pharmaceuticals, INC. | $45.59 | 2019-2023 | Ultomiris |
| Incyte Corporation | $43.80 | 2024-2025 | Jakafi |
| Glaxosmithkline, LLC. | $42.42 | 2024 | Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $41.12 | 2019 | |
| Viiv Healthcare Company | $39.07 | 2019 | |
| Pharmacosmos Therapeutics INC. | $39.03 | 2023-2024 | Monoferric |
| Jazz Pharmaceuticals INC. | $34.77 | 2023 | Zepzelca |
| Blueprint Medicines Corporation | $29.91 | 2025 | Ayvakit |
| Abbvie INC. | $29.53 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.80 | 2023 | |
| Myriad Genetic Laboratories, INC. | $23.57 | 2023 | Myrisk |
| Azurity Pharmaceuticals, INC. | $22.00 | 2025 | Danziten |
| Tersera Therapeutics LLC | $20.26 | 2023 | Zoladex |
| Kite Pharma, INC. | $19.44 | 2023 | |
| Array Biopharma INC | $18.08 | 2023 | Mektovi, Braftovi |
| Servier Pharmaceuticals LLC | $17.40 | 2023 | |
| Mirati Therapeutics, INC. | $17.38 | 2023 | Krazati |
| G1 Therapeutics, INC. | $16.97 | 2023 | Cosela |
| Allergan, INC. | $16.38 | 2019 | |
| Verastem, INC. | $13.43 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anibal Drelichman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.